Wegovy vs Zepbound (US): Which FDA-approved weekly weight-loss injection is best for you?

ByGLP1-Consultant

TL;DR

  • Wegovy® (semaglutide 2.4 mg) and Zepbound® (tirzepatide) are FDA-approved in the U.S. for chronic weight management in eligible adults, used with diet and activity changes.
  • How they work: Wegovy is a GLP‑1 receptor agonist; Zepbound is a dual GIP/GLP‑1 receptor agonist.
  • Average trial results: tirzepatide generally produced more average weight loss than semaglutide 2.4 mg in head-to-head research in adults with obesity without diabetes—but individual results vary.
  • Most common side effects are gastrointestinal (nausea, diarrhea, constipation, vomiting), especially during dose increases.
  • Both have a boxed warning related to thyroid C‑cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
  • In real life, the “best” choice often comes down to your medical history, tolerability, and insurance/availability.

Educational only, not medical advice. Your clinician should decide what’s appropriate for you.

Key takeaways

  • If your goal is maximizing average weight loss, Zepbound may be favored based on study averages.
  • If you’ve tried semaglutide and tolerated it well—or your plan covers it—Wegovy may be the more realistic long-term option.
  • If you have type 2 diabetes, your clinician may frame the discussion around diabetes-indicated brands too (Ozempic/Mounjaro).
  • Safe, consistent access matters: a medication you can take reliably for months is typically more useful than one you can’t get.

Quick comparison (at a glance)

What they are

  • Wegovy: semaglutide injection (weekly), GLP‑1 medication.
  • Zepbound: tirzepatide injection (weekly), GIP + GLP‑1 medication.

FDA-approved purpose (U.S.)

  • Both: chronic weight management in eligible adults (see labeling for criteria).

How often

  • Both: once weekly subcutaneous injection.

Typical GI side effects

  • Both: nausea, diarrhea, constipation, vomiting, abdominal pain, indigestion.

Biggest practical differences

  • Mechanism (GLP‑1 only vs dual incretin)
  • Average trial weight-loss magnitude (tirzepatide higher on average)
  • Dose strengths and titration schedules
  • Insurance coverage and availability

Short answer

Wegovy and Zepbound are FDA-approved weekly injections for chronic weight management in eligible U.S. adults. Wegovy contains semaglutide (a GLP‑1 receptor agonist) and Zepbound contains tirzepatide (a dual GIP/GLP‑1 receptor agonist). In clinical studies, tirzepatide generally led to greater average weight loss than semaglutide 2.4 mg, but individual response, side effects, contraindications, drug availability, and insurance coverage determine which option is best for a given patient.

What are Wegovy and Zepbound?

Wegovy (semaglutide 2.4 mg)

Wegovy is an FDA-approved prescription medication for chronic weight management. It uses semaglutide, a GLP‑1 receptor agonist, delivered by a once-weekly injection pen.

People often confuse Wegovy with other semaglutide brands:

  • Ozempic® (semaglutide) — FDA-approved for type 2 diabetes (and cardiovascular risk reduction in certain adults with type 2 diabetes).
  • Rybelsus® (oral semaglutide) — FDA-approved for type 2 diabetes.

If you’re deciding between the two semaglutide brands, read: Ozempic vs Wegovy.

Zepbound (tirzepatide)

Zepbound is an FDA-approved prescription medication for chronic weight management. It uses tirzepatide, a dual GIP/GLP‑1 receptor agonist.

Zepbound’s “sister brand” is:

  • Mounjaro® (tirzepatide) — FDA-approved for type 2 diabetes.

If that’s your situation, read: Mounjaro vs Zepbound.

Who qualifies in the U.S.? (Eligibility, simplified)

Most U.S. labeling and insurance criteria revolve around BMI plus health conditions.

Common eligibility pattern (for adults)

  • BMI ≥ 30 (obesity), or
  • BMI ≥ 27 (overweight) with at least one weight-related condition

Weight-related conditions can include things like high blood pressure, high cholesterol, or type 2 diabetes.

BMI is imperfect. It does not directly measure body fat, distribution of fat, muscle mass, or health. But it is commonly used in guidelines and insurance rules.

CDC background on BMI for adults: https://www.cdc.gov/bmi/adult-calculator/index.html

How they work (patient-friendly science)

GLP‑1 (both medications target this)

GLP‑1 is a gut hormone your body releases after eating. GLP‑1 medications can:

  • Increase feelings of fullness
  • Reduce appetite
  • Reduce cravings for some people
  • Slow stomach emptying (especially early in treatment)
  • Improve blood sugar control (more relevant if you have diabetes)

GIP (Zepbound targets this too)

Tirzepatide also activates the GIP receptor. Researchers believe the combined GIP/GLP‑1 activity can amplify metabolic and appetite effects, contributing to greater average weight loss in trials.

Effectiveness: what the research suggests (and how to interpret it)

The biggest mistake: assuming you’ll get the average

Clinical trials report averages—real patients vary widely.

Your results depend on things like:

  • the dose you can tolerate and maintain
  • how consistently you can access the medication
  • sleep, stress, and meal patterns
  • other medications that affect appetite or weight
  • underlying conditions (e.g., insulin resistance, PCOS)

What studies generally show

  • Both Wegovy and Zepbound produce clinically meaningful weight loss compared with placebo.
  • In head-to-head research in adults with obesity without diabetes, tirzepatide produced greater average weight loss than semaglutide 2.4 mg.

What “more average weight loss” does not mean

It does not mean:

  • Wegovy “doesn’t work”
  • Zepbound is right for everyone
  • you should chase the highest dose as fast as possible

Tolerability and consistency matter.

Dosing and titration: why the ramp-up is part of the treatment

Why doses increase slowly

Both medications typically start low and increase every few weeks. The main reason is side effect management, especially nausea and vomiting.

Typical weekly dosing concepts (high level)

  • Wegovy is titrated to a 2.4 mg maintenance dose for many patients.
  • Zepbound is titrated across dose levels (e.g., 2.5 mg starting dose, then higher maintenance doses depending on response and tolerability).

Your prescriber may modify the schedule. Always follow the FDA label and your clinician’s instructions.

What patients often feel during titration

Many people notice a pattern:

  • the first 24–72 hours after an injection can feel different than the end of the week
  • nausea may spike after dose increases
  • appetite suppression may strengthen after dose increases
  • weight can plateau for weeks, then drop again

Side effects: what’s common, what’s serious, and what’s “call the doctor”

Common side effects (both)

The most common are gastrointestinal:

  • nausea
  • diarrhea
  • constipation
  • vomiting
  • abdominal pain
  • indigestion / reflux

These are often dose-related and more common early in treatment.

Serious risks in FDA labeling (both)

Bring these up with your clinician, especially if you have risk factors:

  • pancreatitis
  • gallbladder disease (including gallstones)
  • kidney problems (often from dehydration due to vomiting/diarrhea)
  • severe allergic reactions

Boxed warning: thyroid C‑cell tumors

Both medications have a boxed warning and are contraindicated in people with:

  • personal/family history of MTC, or
  • MEN2

A practical safety mindset

Most side effects are manageable, but persistent vomiting, severe abdominal pain, or inability to keep fluids down is not something to “push through.”

For a deeper safety guide, read: GLP‑1 side effects: what to expect and when to call a doctor.

Cost and insurance coverage in the U.S. (often the deciding factor)

Why coverage varies widely

U.S. coverage depends on:

  • employer plan design (many plans exclude weight-loss drugs)
  • state Medicaid rules
  • prior authorization criteria and reauthorization requirements

Even within the same insurer, two people can have totally different coverage.

Common prior authorization requirements

Plans may ask for:

  • BMI documentation
  • weight-related conditions
  • a history of lifestyle attempts
  • follow-up weight response (e.g., continued coverage only if a certain % weight loss occurs)

If you’re considering compounded alternatives

Many people look at compounded semaglutide/tirzepatide because of cost or access.

Before you do, read: Compounded semaglutide/tirzepatide: what the FDA warns about.

Availability: what to do if your dose is hard to find

Shortages and uneven pharmacy supply have impacted these medications.

Patients often ask their clinician about:

  • whether a different dose is available and how that affects titration
  • using mail-order or specialty pharmacies through insurance
  • what to do if they miss a week or more due to supply

Avoid buying “semaglutide” or “tirzepatide” from unknown online sellers.

Choosing between Wegovy and Zepbound: a patient-centered decision guide

Step 1: clarify the primary goal

  • Weight management
  • Diabetes management
  • Cardiovascular risk reduction
  • Sleep apnea/other weight-related conditions (if applicable)

Step 2: review safety and contraindications

Ask specifically about:

  • MTC/MEN2 history
  • pancreatitis history
  • gallbladder disease history
  • kidney disease
  • pregnancy plans

Step 3: consider “tolerability fit”

Questions to reflect on:

  • Are you prone to reflux or nausea?
  • Do you have a job/life routine where a rough day or two after injection is manageable?

Step 4: map your access and budget

  • What’s covered?
  • What is the prior authorization timeline?
  • Is the medication reliably in stock locally?

Step 5: agree on what success looks like

Success can include:

  • improved mobility
  • improved blood pressure/lipids
  • improved sleep apnea symptoms
  • reduced need for certain medications

Weight is not the only outcome.

Frequently asked questions

Is Zepbound “better” than Wegovy?

On average in trials, tirzepatide led to greater weight loss than semaglutide 2.4 mg. But “better” depends on your health history, side effects, and access.

Which causes less nausea?

Both can cause nausea. Some patients tolerate one better than the other, and titration pace matters.

Can I switch between them?

Switching should be planned with your prescriber. Many clinicians restart at a lower dose when switching to reduce side effects.

What if I have type 2 diabetes?

Your clinician may discuss diabetes-indicated brands too:

Are these the same as compounded versions?

No. Wegovy and Zepbound are FDA-approved products with standardized manufacturing and labeling. Compounded products vary.

References (FDA + major medical sources)

Medical disclaimer

This content is for general educational purposes only and does not replace medical advice, diagnosis, or treatment from a licensed clinician. Do not start, stop, or change prescription medications without medical guidance. If you think you may have a medical emergency, call 911.